Gilead and Spring Bank study HBV combo therapy in trial collaboration
Gilead Sciences Inc. and Spring Bank Pharmaceuticals Inc. agreed to conduct a Phase II trial investigating the combination of Gilead's Viread (tenofovir) with Spring Bank's SB9200 for hepatitis B virus.
- Intra-Biotech Deal
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com